Revolution Medicines, Inc. (RVMD) income statement
NASDAQ · Healthcare · Biotechnology · 883 employees · CEO Mark A. Goldsmith
- Price
- $191.31 +0.55%
- Market cap
- $41B
- Enterprise value
- $40.8B
- Last report
- Q2 '26 filed 2026-08-05
- Next report
- 2026-11-04 EPS est. -$2.35
Revolution Medicines, Inc. (RVMD) reported revenue of $0 for Q2 '26 (– year on year), operating income of -$505M (– of revenue) and net income of -$644M. Over the last four quarters revenue was $0.
Income statement
| Income statement | Trend | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | Q2 '26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $742K | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | |
| Cost of revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $4.7M | $4.54M | $0 | |
| Gross profit | $0 | $742K | $0 | $0 | $0 | $0 | $0 | $0 | $0 | -$4.7M | -$4.54M | $0 | |
| Research & development | $108M | $148M | $118M | $135M | $152M | $188M | $206M | $224M | $263M | $293M | $344M | $395M | |
| General & administrative | $15.5M | $32.2M | $22.8M | $21.7M | $24M | $28.2M | $35M | $40.6M | $52.8M | $64.3M | $101M | $110M | |
| Other operating expenses | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | -$4.54M | $0 | |
| Operating expenses | $123M | $181M | $141M | $157M | $176M | $216M | $241M | $265M | $315M | $357M | $441M | $505M | |
| Operating income | -$123M | -$180M | -$141M | -$157M | -$176M | -$216M | -$241M | -$265M | -$315M | -$362M | -$445M | -$505M | |
| Interest income | $10.9M | $18.7M | $23.8M | $21.5M | $20.4M | $21.2M | $24.9M | $22.4M | $22.1M | $21.3M | $19.5M | $35.6M | |
| Interest expense | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $11.4M | $11.9M | $12.2M | $23.8M | |
| Other non-operating income (gains on investments, FX ...) | -$10.9M | -$47.6M | -$24.9M | -$23.4M | -$19.4M | -$21M | -$27.3M | -$16.9M | -$21.5M | -$8.67M | -$3.6M | $115M | |
| Total non-operating income | $10.9M | $18.8M | $24.9M | $23.4M | $19.4M | $21M | $27.3M | $16.9M | $10.1M | -$3.27M | -$8.59M | -$139M | |
| Income before tax | -$112M | -$161M | -$116M | -$133M | -$156M | -$195M | -$213M | -$248M | -$305M | -$365M | -$454M | -$644M | |
| Income tax | -$3.87M | $343K | $0 | $0 | $0 | -$753K | $0 | $0 | $0 | $0 | $0 | $0 | |
| Net income | -$108M | -$162M | -$116M | -$133M | -$156M | -$195M | -$213M | -$248M | -$305M | -$365M | -$454M | -$644M | |
| EPS (basic) | -$0.99 | -$1.14 | -$0.70 | -$0.81 | -$0.94 | -$1.13 | -$1.13 | -$1.31 | -$1.61 | -$1.90 | -$2.29 | -$3.06 | |
| EPS (diluted) | -$0.99 | -$1.14 | -$0.70 | -$0.81 | -$0.94 | -$1.13 | -$1.13 | -$1.31 | -$1.61 | -$1.90 | -$2.29 | -$3.06 | |
| Shares (basic, weighted) | 109M | 141M | 165M | 165M | 167M | 168M | 188M | 188M | 189M | 190M | 198M | 211M | |
| Shares (diluted, weighted) | 109M | 141M | 165M | 165M | 167M | 168M | 188M | 188M | 189M | 190M | 198M | 211M | |
| Depreciation & amortization | $2.15M | $2.86M | $2.76M | $2.8M | $2.88M | $3.39M | $3.72M | $3.8M | $4.34M | $4.7M | $4.54M | $4.5M | |
| EBITDA | -$110M | -$130M | -$113M | -$130M | -$153M | -$192M | -$210M | -$244M | -$289M | -$348M | -$437M | -$616M |
| Income statement | Trend | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $20.2M | $50M | $43M | $29.4M | $35.4M | $11.6M | $0 | $0 | |
| Cost of revenue | $26.6M | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $16.6M | |
| Gross profit | -$26.6M | $20.2M | $50M | $43M | $29.4M | $35.4M | $11.6M | $0 | -$16.6M | |
| Research & development | $26.6M | $51.1M | $91.8M | $132M | $187M | $253M | $423M | $592M | $979M | |
| General & administrative | $4.54M | $9.41M | $12.4M | $21.4M | $30.5M | $40.6M | $75.6M | $97.3M | $187M | |
| Other operating expenses | -$26.6M | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | |
| Operating expenses | $4.54M | $60.5M | $104M | $154M | $217M | $294M | $499M | $690M | $1.17B | |
| Operating income | -$31.1M | -$40.3M | -$54.1M | -$111M | -$188M | -$258M | -$487M | -$690M | -$1.18B | |
| Interest income | $105K | $777K | $2.19M | $2.24M | $929K | $9.15M | $47.5M | $86.9M | $90.7M | |
| Interest expense | $103K | $116K | $106K | $71K | $12K | $0 | $303K | $0 | $24.2M | |
| Other non-operating income (gains on investments, FX ...) | -$105K | $1.34M | -$2.19M | -$2.24M | -$929K | -$9.15M | -$47.6M | -$88.7M | -$75.3M | |
| Total non-operating income | $2K | -$1.46M | $2.08M | $2.17M | $917K | $9.15M | $47.3M | $88.7M | $51.1M | |
| Income before tax | -$31.1M | -$41.8M | -$52M | -$109M | -$187M | -$249M | -$440M | -$601M | -$1.13B | |
| Income tax | $105K | $0 | -$4.37M | -$371K | $0 | -$420K | -$3.52M | -$753K | $0 | |
| Net income | -$31.1M | -$41.8M | -$47.7M | -$108M | -$187M | -$249M | -$436M | -$600M | -$1.13B | |
| EPS (basic) | -$0.85 | -$1.15 | -$1.31 | -$1.62 | -$2.47 | -$3.08 | -$3.86 | -$3.58 | -$5.95 | |
| EPS (diluted) | -$0.85 | -$1.15 | -$1.31 | -$1.62 | -$2.47 | -$3.08 | -$3.86 | -$3.58 | -$5.95 | |
| Shares (basic, weighted) | 36.5M | 36.5M | 36.5M | 66.6M | 72.8M | 80.6M | 113M | 168M | 190M | |
| Shares (diluted, weighted) | 36.5M | 36.5M | 36.5M | 66.6M | 72.8M | 80.6M | 113M | 168M | 190M | |
| Depreciation & amortization | $1.19M | $1.76M | $3.34M | $6.55M | $7.33M | $9.66M | $9.31M | $11.8M | $16.6M | |
| EBITDA | -$29.8M | -$39.9M | -$48.6M | -$102M | -$180M | -$239M | -$430M | -$589M | -$1.09B |
Standardised by Financial Modeling Prep from the company's filings; outflows and costs keep the sign the provider reports. Hover a period for its end date. Amounts in USD.
Revenue, operating income and growth
quarterlyMargins
quarterlyCosts as % of revenue
quarterlyThe other statements
Sources
Statements, segment revenue, metrics, estimates: Financial Modeling Prep. Segment profits and every reported line: SEC EDGAR (XBRL). Filings read: 10-Q 2026-06-30, 10-Q 2026-03-31, 10-K 2025-12-31, 10-Q 2025-09-30, 10-Q 2025-06-30, 10-Q 2025-03-31, 10-K 2024-12-31, 10-Q 2024-09-30, 10-Q 2024-06-30
Data as of 2026-11-02